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Abstract
Background: The shRNA lentiviral vector was constructed to silence c-Ski expression in cardiac mus-
cle cells, with the aim of exploring the role of c-Ski in transforming growth factor b1 (TGF-b1)-induced 
epithelial-mesenchymal transitions (EMT) in H9C2 cells. 
Methods: Real-time polymerase chain reaction (RT-PCR) and western blot were used to detect c-Ski ex-
pression at protein and messenger ribonucleic acid (mRNA) levels in 5 different cell lines. Then, lentiviral 
vector was constructed to silence or overexpress c-Ski in H9C2 cells. MTT and/or soft agar assay and tran-
swell assay were used to detect cell proliferation and migration, respectively. The expression levels of c-Ski 
under different concentrations of TGF-b1 stimulation were detected by RT-qPCR and immunocytochemi-
cal analysis. In the presence or absence of TGF-b1 stimulation, the proteins’ expression levels of a-SMA, FN 
and E-cadherin, which are closely correlated with the process of EMT, were measured by western blot after  
c-Ski silencing or overexpression. Meanwhile, the effect of c-Ski on Samd3 phosphorylation with TGF-b1  
stimulation was investigated.
Results: There is a high expression of c-Ski at protein and mRNA levels in H9C2 cell line, which 
first demonstrated the presence of c-Ski expression in H9C2 cells. Overexpression of c-Ski significantly 
increased H9C2 cell proliferation. The ability of c-Ski gene silencing to suppress cell proliferation was 
gradually enhanced, and inhibition efficiency was the highest after 6 to 7 d of transfection. Moreover, 
H9C2 cells with c-Ski knockdown gained significantly aggressive invasive potential when compared 
with the control group. TGF-b1 stimulation could dose-independently reduce c-Ski expression in H9C2 
cells and lead to obvious down-regulated expression of E-cadherin. Interestingly, c-Ski could restore  
E-cadherin expression while suppressing a-SMA and/or FN expression stimulated by TGF-b1. How-
ever, shRNA-induced c-Ski knockdown aggravated only the TGF-b1-induced EMT. Moreover, c-Ski-
-shRNA also promoted the phosphorylation of Samd3 induced by TGF-b1.
Conclusions: c-Ski expression in cardiac muscle cells could be down-regulated by TGF-b1. Silencing 
of c-Ski gene was accompanied by down-regulation of E-cadherin, up-regulation of a-SMA and/or FN 
and Smad3 phosphorylation induced by TGF-b1, promoting EMT process. Therefore, c-Ski may be 
closely associated with TGF-b1-induced EMT and play an important role in cardiac fibrosis develop-
ment and progression. (Cardiol J 2019; 26, 1: 66–76)
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Epithelial-mesenchymal transition (EMT), 
a pathological process that is highly regulated, has 
already been identified as a critical mechanism for 
controlling either cardiac development or cardiac 
fibrosis [1]. Although the traditional view that 
the resident fibroblasts and their derived myofi-
broblasts play a crucial role in fibrosis still holds, 
increasing amounts of data collected in the past 
decade suggest that EMT is a direct contributor 
to the fibroblast/myofibroblast pool during fibro-
genesis [2]. In adults, abnormal activation of EMT 
and differentiation of EMT-derived fibroblast-like 
cells to collagen-producing myofibroblasts play 
a significant role in the development and progres-
sion of fibrosis in organs such as heart and lung 
[3, 4]. Therefore, in addition to targeting fibroblast 
activation and proliferation, prevention of EMT 
may be another effective strategy to mediate car-
diac fibrosis.
The c-Ski gene was first found in chicken 
embryonic cells infected with the avian leukaemia 
transformation defect virus, Bratislava77, by Li et 
al. [5] in 1986. c-Ski expression was found in all 
tissues of mice and was most abundant in nerve 
and muscle tissues. The expression level of c-Ski 
in other tissues was low, suggesting that c-Ski may 
play an important role in neurological and muscular 
tissue function [6]. Previous studies have shown 
that in the post-traumatic repair process, c-Ski can 
promote fibroblast proliferation [7]. 
There is increasing evidence that cytokines 
play a critical role in EMT, especially transforming 
growth factor b1 (TGF-b1). TGF-b plays a key role 
in EMT progression [8]. TGF-b1-induced EMT can 
promote myofibroblast transformation, which is 
prominently involved in fibrotic processes [9]. To 
further explore the role of c-Ski in TGF-b1-induced 
EMT and its related function in cardiac fibrosis, 
the present study used the lentivirus system to 
silence expression of c-Ski and applied TGF-b1 
to stimulate EMT in H9C2 cells to evaluate the 
biological function of c-Ski in EMT. 
Methods
Reagents
Reagents included: RPMI1640/DMEM me-
dium and foetal bovine serum (FBS) (HyClone, 
USA); transfection reagent X-tremeGENE™ HP, 
(Roche, Germany); TRIzol (Life Technologies, 
USA); polymerase chain reaction (PCR) instrument 
(Bio-Rad, USA); cDNA synthesis kit (Fermen-
tas, USA); SYBR qPCR Mix/HiScript II (Vazyme 
Biotech Co., Ltd, Nanjing, China); TGF-b1 (R&D, 
USA); Thiazolyl blue (MTT) (Sigma, USA); anti-c-
-Ski (CST, 1: 1000), anti-a-SMA (Abcam, 1: 1000), 
anti-fibronectin (FN) (Abcam, 1: 1000), anti-p-
-Smad3 (Abcam, 1: 1000), anti-Smad3 (Abcam, 1: 
1000), anti-E-cadherin (Abcam, 1: 1000), anti-b- 
-actin (Abcam, 1: 3000) and HRP labelled second-
ary antibody (CST, 1: 3000). 
The design of shRNA 
The synthetic oligonucleotides of shRNA 
(3 pairs of c-Ski shRNA synthesized by Sangon 
Biotech, Co.) were designed by using shRNA 
online design software (http://www.ambion.com). 
As listed in Table 1, the specific sequences were 
verified by BLAST analysis, and no homology with 
other human coding sequences was found. shRNA 
without homology to c-Ski mRNA and other genes 
were selected as the control (shScramble).
Cell culture
Cells were cultured in RPMI1640 and DMEM 
medium, containing 10% FBS and ampicillin-
streptomycin (100 U/mL), at 37°C in a 5% CO2 
saturated humidity environment. 
Construction of pLKO.1/c-Ski  
or sh-c-Ski vector 
Oligo sh-c-Ski or c-Ski was diluted with ultra-
pure water to the appropriate concentration. The 
annealing conditions were 94°C 10 min, 70°C 
10 min, and 50°C water at room temperature. 
The vector plko-GFP-TRC was digested with 
Age I, EcoR I restriction endonuclease for 1 h at 
37°C. The treated sh-c-Ski or c-Ski was mixed 
with vector, and T4 ligase was added and then 
reacted at 22°C for 3 h. The ligated products were 
added into competent cells, and 1 mL LB medium 
was added. After activation at 37°C for 40 min at 
300 r/min, the cells were centrifuged at 4000 r/ 
/min for 3 min, and then the supernatant was dis-
carded. The next day, a single clone was selected 
and inoculated in LB medium, shaking at 37°C 
300 r/min overnight. Plasmids were extracted from 
the bacterial solution, and the purity was deter-
mined. The empty vector (Control), shScramble 
vector and c-Ski-shRNA vector were digested 
with restriction endonuclease Xho I at 37°C for 
1 h. Then, 4 μL digested products or markers was 
added to 10 × loading buffer and then loaded on 
0.8% agarose gel for gel electrophoresis.
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The immunofluorescence assay for c-Ski 
expression after transfection
293T cells were cultured in DMEM medium 
containing 10% FBS and ampicillin-streptomycin 
(100 U/mL) at 37°C in a saturated humidity envi-
ronment with 5% CO2 and digested with 0.25% 
trypsin. The culture medium was replaced by MEM 
medium 2 h before the experiment. Next, 2.5 μg of 
c-Ski-shRNA vector, 2.5 μg of D8.91 and 0.25 μg of 
vesicular stomatitis virus G glycoprotein (VsV-g) 
were homogeneously mixed. At the same time, 
the shScramble group and GFP control group were 
set up. A total of D8.91 and VsV-g helper plasmids 
were used, then 10 μL of X-tremeGENE HP DNA 
Transfection Reagent was added and let stand for 
20 min at room temperature. The transfection com-
plex was added to the culture medium for 24 h and 
48 h, and the supernatant was added to the H9C2 
cell culture medium. After adding puromycin (1 μg/ 
/mL), cells were screened for fluorescence. c-Ski 
expression in the c-Ski-shRNA group, shScramble 
group and GFP control group was detected by im-
munofluorescence.
Cell proliferation was detected by MTT assay
Four groups of H9C2 cells in logarithmic 
growth phase were inoculated in 96-well plates 
(5 × 103 cells per well) at 24, 48, 72 and 96 h, and 
three replicates were set at each time point. After 
incubating at 37°C for 4 h with 20 μL MTT (5 mg/ 
/mL), 200 μL DMSO was added. After 10 min vi-
bration, the absorbance (A) value of the mixture 
was measured at 560 nm using a microplate reader. 
The proliferation rate of these four groups of cells 
was calculated.
Soft agar colony formation assay
Four groups of cells were digested with trypsin 
when the fusion degree reached 70% to 80% and 
were then washed 3 times with PBS. The cells 
were re-suspended in a medium containing low-
melting agar and then plated at a density of 1 × 103 
cells per 6 cm dish, and 3 duplicate dishes per set. 
After 4 d, 5 d, 6 d and 7 d, cells were fixed with 4% 
paraformaldehyde and stained with crystal violet; 
the cell clones in each dish were counted for the 
colony-formation rate calculation, and the experi-
ment was repeated 3 times. The colony-formation 
rate = (cell clones/inoculum density) × 100%.
Invasion assay
Three groups of H9C2 cells were incubated 
with 0.25% trypsin/EDTA and re-suspended in 
serum-free RPMI1640 to 5 × 105 cells per mL 
after 72 h culture. Then, 100 μL of cell suspension 
was added to the transwell chamber, and the lower 
layer was added with 600 μL RPMI 1640 containing 
10% FBS; each set of 3 duplicates. The transwell 
chamber was removed after 6 h incubation, and 
cells were wiped that did not pass through the 
membrane with a cotton swab. Then, cells were 
immobilized with ethanol and air dried and stained 
with 0.1% crystal violet. The cell numbers in the 
upper, lower, left, right and middle visual fields 
were all counted under light microscopy.
RT-PCR
The expression of c-Ski mRNA in different cell 
lines and different concentrations of TGF-b1-treat-
ed groups was detected. The cells were collected, 
and the total RNA was extracted with TRIzol 
Table 1. The gene sequences of shRNA oligo for vector construction and the primers for polymerase 
chain reaction.
Primers Gene sequences
c-Ski-shRNA1 F1: 5’-CCG GAC GTC TTA CCG TGC CTA TTA CCT CGA GGT AAT AGG CAC GGT AAG ACG TTT TTG-3’
R1: 5’-AAT TCA AAA AAC GTC TTA CCG TGC CTA TTA CCT CGA GGT AAT AGG CAC GGT AAG ACGT-3’
c-Ski-shRNA2 F2: 5’-CCG GGA ATC TGC CAC TCT CAG AAT ACT CGA GTA TTC TGA GAG TGG CAG ATT CTT TTT G-3’
R2: 5’-AAT TCA AAA AGA ATC TGC CAC TCT CAG AAT ACT CGA GTA TTC TGA GAG TGG CAG ATT C-3’
c-Ski-shRNA3 F3: 5’-CCG GCA GTG TCA GCG AGT GAG AAA GCT CGA GCT TTC TCA CTC GCT GAC ACT GTT TTT G-3’
R3: 5’-AAT TCA AAA ACA GTG TCA GCG AGT GAG AAA GCT CGA GCT TTC TCA CTC GCT GAC ACT G-3’
shScramble 5’-CCG GCC TAA GGT TAA GTC GCC CTC GCT CGA GCG AGG GCG ACT TAA CCT TAG GTT TTT G-3’
c-Ski F 5’- CGA GAC AGC TTC TAC TCC TAC A-3’
R 5’- TAG TAA GGG GTT CTG GTG CC-3’
GAPDH F 5’-GGA GAT TGT TGC CAT CAA CG-3’
R 5’-TTG GTG GTG CAG GAT GCA TT-3’
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(according to the manufacturer instructions). The 
total RNA was reverse transcribed to cDNA using 
MMLV reverse transcriptase. PCR was carried out 
by adding PCR buffer, primers (Table 1) and the 
cDNA (as a template). The PCR reaction conditions 
were as follows: a pre-denaturation at 95°C for 
2 min followed by 35 cycles of denaturing at 94°C 
for 30 s, annealing at 56°C for 30 s, extension at 
72°C for 1 min, and a final extension at 72°C for 
10 min. Three replicate wells were set up for each 
sample.
Western blot assay 
After discarding the culture medium, cells 
were rinsed twice with cold PBS, and then lysed 
in RIPA lysate on ice. After incubation at 95°C for 
5 to 10 min, 3 μL was taken for quantification by 
the BCA method. Boiled proteins were stored at 
–20°C until used. A 10% SDS-PAGE gel was pre-
pared, the sample loaded, and the gel was run. After 
electrophoresis, the proteins were transferred to 
PVDF membrane at 200 mA constant current for 
1.5 h. Then, the PVDF membrane was blocked with 
5% non-fat milk for 1 h and incubated overnight 
at 4°C after adding the primary antibody. The next 
day, after adding the secondary antibody for 1 h 
co-incubation at room temperature, the membrane 
was washed 3 times with TBST. The membrane 
was removed, ECL substrate was added, and then 
the luminescence signal was recorded in a dark 
chamber. 
Immunocytochemical analysis
The logarithmic phase H9C2 cells were di-
vided into four groups, and the cell climbing slides 
were prepared for immunocytochemical analysis. 
Cells were treated with different concentrations 
of TGF-b1 (0, 2, 4 and 8 ng/mL) for 48 h. After 
washing 3 times with PBS, the cells were im-
mediately fixed with 4% paraformaldehyde for 
15 min. After removing paraformaldehyde by 
washing, the cells were permeabilized with 0.1% 
Triton-X 100, blocked with 3% boovine serum al-
bumin, and incubated with c-Ski antibody overnight 
at 4°C. All slides were analyzed using an Olympus 
BX51 microscope to evaluate c-Ski protein expres-
sion after 1 h of co-incubation with HRP-labelled 
secondary antibodies.
Statistical analysis
The measurement data were normally dis-
tributed with homogeneity of variance and were 
expressed as the mean ± standard deviation. 
Independent data between the two groups were 
compared by paired t-test design. Comparison 
among groups was made by one-way ANOVA. If 
the variance was not uniform, Dunnett’s T3 method 
was used. Count data were compared by c2 test. 
SPSS13.0 software was used for statistical analysis. 
p < 0.05 was considered significant.
Results
c-Ski expression in cardiomyocytes
The present study investigated the expression 
of c-Ski at protein and mRNA levels in different 
cell lines, among which, the colorectal cancer cell 
line, SW620, showed significantly higher c-Ski 
expression than that in H9C2 cell line; wherein, 
both the expression of mRNA (t = 3.880, p < 0.05) 
and protein (t = 14.29, p < 0.001) was significantly 
different. Notably, in the H9C2 cell line, a high 
expression of c-Ski at protein and mRNA level 
was also detected, which first demonstrated the 
presence of c-Ski expression in H9C2 cells (Fig. 1). 
The results of the expression of c-Ski mRNA and 
protein were the average of 5 duplicates, each 
sample N = 5. The data were consistent with 
homogeneity of variance by Levene test, and K-S 
normal test results suggest that the data were 
Gaussian distribution.
Down-regulation of c-Ski in H9C2 cells 
c-Ski was silenced or overexpressed with 
lentivirus technology to observe the effect of c-Ski 
on the biological function of cardiomyocyte. Three 
pairs of c-Ski-shRNA sequences were designed, 
linked to pLKO vector and then transformed to the 
competent cells. The plasmids were extracted and 
identified by enzyme digestion. The expression of 
c-Ski protein was detected by western blot after 
48 h of transfection. As Figure 2A shows, these three 
pairs of sequences had a function of interference. In 
addition, the shRNA-3 gene silencing of the c-Ski 
gene in H9C2 cells was the most efficient (p < 0.01, 
compared with control) and was used in follow-up 
experiments. The results of gel electrophoresis 
showed that c-Ski expression in the c-Ski-shRNA 
group was significantly lower than that of the control 
group (Fig. 2B, p < 0.001, F = 126.8). From the 
fluorescence results, the cell infection rate reached 
98% (Fig. 2C). Meanwhile, to confirm whether the 
decreased expression of c-Ski could still present 
in cells after 7 d, the cells were collected after 7 d 
of transfection with empty vector, c-Ski vector or 
sh-c-Ski vector to measure the protein expression 
of c-Ski. As shown in Figure 2D, the transfec-
tion of c-Ski induced an overexpression of c-Ski 
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Figure 1. The expression of c-Ski mRNA and protein in different cell lines. A. mRNA expression level. B. Protein 
expression level; using software to calculate the gray value of the bands; **vs. SW620, p < 0.01; #vs. RKO, p < 0.05; 
Dvs. LoVo, p < 0.05.
Figure 2. The construction of c-Ski or sh-c-Ski lentiviral vector and the transfection of H9C2 cells. A. Western blot as-
say of the c-Ski protein expression in H9C2 cells in different groups. B. The c-Ski-shRNA vector was confirmed by gel 
electrophoresis. C. The fluorescent intensity of three groups of H9C2 cells 48 h post transfection (scale bar indicated 
100 μm). D. The knock down efficiency of c-Ski was detected by western blot in H9C2 cells after 7 d transfection. 
Upper panel: the original pictures; lower panel: the quantification of the gray scale of the bands in different treated 
groups by software ImageJ; *p < 0.05, **p < 0.01, compared with the GFP control; ##p < 0.01, compared with the 
shScramble group. #p < 0.05, compared with the shScramble group.
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(p < 0.001 vs. control group), while in the c-Ski-
shRNA group, c-Ski could be significantly sup-
pressed (p < 0.001 vs. control group). Therefore, 
the above results indicated successful overexpres-
sion and down-regulation of c-Ski in H9C2 cells. 
Effect of c-Ski and sh-c-Ski  
on cell proliferation
The changes of cell proliferation after c-Ski 
silencing or overexpression were analyzed by 
MTT assay and soft agar colony formation assay. 
Results showed that a significant increase of cell 
proliferation could be observed in c-Ski overex-
pression group. However, after stably silencing 
c-Ski, the proliferation rates of H9C2 cells were 
not significantly different within 96 h transfection 
compared with the GFP control and shScramble 
groups at different time points, but the difference 
was significant compared with the overexpression 
group at 96 h after the transfection (p < 0.05), as 
shown in Figure 3A. Meanwhile, the ability of c-Ski 
gene silencing-suppressed cell proliferation was 
gradually enhanced, and the inhibition efficiency 
was the highest after 6 to 7 d of transfection, as 
shown in the results of the soft agar colony for-
mation assay (Fig. 3B; p < 0.05, compared with 
GFP control, p < 0.01, compared with the c-Ski 
overexpression group). 
Effect of c-Ski-shRNA on migration ability 
of cardiomyocytes 
As shown in Figure 4A, the transwell assay 
showed that the number of invasive cells in the 
c-Ski-shRNA group was (278 ± 36/field) signifi-
cantly higher than in the control group (52 ± 15/
field) and the shScramble group (45 ± 13/field) 
Figure 3. Effect of c-Ski or c-Ski-shRNA on cell proliferation in H9C2 cells. A. MTT assay for detecting the cell viability 
after transfection. B. The long-term efficiency of c-Ski on cell proliferation by soft agar colony formation assay after 
stable silencing; *p < 0.05, compared with the GFP control; #p < 0.05 and ##p < 0.01, compared with the c-Ski 
overexpression group.
Figure 4. Effect of c-Ski-shRNA on cell proliferation in H9C2 cells. A. Results of the transwell migration test (scale bar 
indicated 50 μm). B. Invasive cells per field were counted; **p < 0.001, compared with the GFP control and shScramble 
groups. 
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(F = 155.9, p < 0.001). This result indicated that 
down-regulation of c-Ski could enhance the inva-
sion of the H9C2 cells at almost 6 times greater 
than the control group (Fig. 4B).
Effect of c-Ski-shRNA on E-cadherin  
expression in H9C2 cells
As shown in Figure 5A, after stimulation with 
the increased concentration of TGF-b1, the expres-
sion of c-Ski protein was significantly suppressed, 
as shown by the gradual decrease of brown-yellow 
area. The qPCR results further confirmed that 
TGF-b1 could down-regulate the c-Ski at mRNA 
level in a dose-dependent manner (Fig. 5B). E-cad-
herin was down-regulated during TGF-b1-induced 
EMT; herein, the expression of E-cadherin in the 
c-Ski-shRNA group (Fig. 5C); after stimulation 
with TGF-b1 was also evaluated; in the control and 
shScramble groups, E-cadherin expression was 
normal in the absence of TGF-b stimulation, but 
it could be down-regulated when stimulated with 
TGF-b in a dose-dependent manner. However, the 
expression of E-cadherin was significantly abol-
ished after down-regulation of c-Ski, and the down-
regulation tendency of E-cadherin was aggregated 
after TGF-b stimulation. This result suggests that 
TGF-b1 could also down-regulate the expression of 
E-cadherin dose-dependently, and this inhibitory 
effect could be enhanced by c-Ski-shRNA. 
Effect of c-Ski-shRNA  
on EMT-related proteins
TGF-b1, an important regulatory factor in 
the fibrosis process, can lead to EMT and fi-
nally induce fibroblasts to transform into myo - 
f ibroblasts and produce extracellular ma-
trix (ECM). Here, post 48 h transfection of c-
Ski, c-Ski-shRNA or shScramble, the H9C2 
cells were stimulated with TGF-b1 (8 ng/mL) 
for 24 h. After being washed with PBS 3 times, 
cells were collected for western blot assay to detect 
the expression of EMT-related proteins (a-SMA, 
FN and E-cadherin). As shown in Figure 6A, 
overexpression of c-Ski could up-regulate the ex-
pression of E-cadherin down-regulated by TGF-b1 
stimulation while suppressing the expression of 
Figure 5. Effect of TGF-b1 on c-Ski expression and c-Ski-shRNA on E-cadherin expression in H9C2 cells. Immunocy-
tochemical analysis (A) and RT-qPCR assay (B) for the protein and mRNA expression of c-Ski with TGF-b1 stimula-
tion. C. Effect of c-Ski-shRNA on E-cadherin expression under different concentrations of TGF-b1 stimulation; D. The 
quantification of the gray scale of the bands in different treated groups by software ImageJ; *p < 0.05, **p < 0.01, 
compared with the GFP control; &p < 0.05, &&p < 0.01, compared with the non-TGF-b1-treated group.
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a-SMA and FN increased by TGF-b1 stimulation. 
However, the knockdown of c-Ski could achieve 
a similar efficiency, as TGF-b1 induced on EMT, 
showing as the down-regulated E-cadherin and 
up-regulated a-SMA and FN in H9C2 cells with-
out TGF-b1 stimulation. Moreover, for TGF-b1-
-stimulated E-cadherin suppression or a-SMA and/ 
/or FN up-regulation, c-Ski-shRNA could enhance 
the effects of TGF-b1. Additionally, c-Ski-shRNA 
promoted the phosphorylation of Smad3, but over-
expressed c-Ski exerted the opposite effect in H9C2 
cells stimulated with TGF-b1, suggesting that sh-
c-Ski could aggravate the TGF-b1-induced EMT.
Discussion 
Studies have shown that c-Ski protein plays 
an important role in nerve, muscle development 
and organ fibrosis and promotes the malignant 
transformation process [6, 7, 10, 11]. High levels 
of expression of c-Ski were reported in several 
tumor cell lines [12, 13]. In the present study, 
a high expression of c-Ski was also observed in 
different colon cancer cell lines, including highly 
metastatic SW620 and HT-29 cells, lowly meta-
static RKO cells and undifferentiated LoVo cells. 
Interestingly, in the H9C2 cell line, a rat cardiac 
Figure 6. Effect of c-Ski on the expression of TGF-b1-induced EMT-related proteins and the phosphorylation of Smad3. 
A. The effect of overexpressed c-Ski on a-SMA, FN and E-cadherin expression in the absence of TGF-b1 stimulation. 
B. Histogram show the quantitative results of Figure 6A. C. The effect of c-Ski-shRNA on expression of a-SMA, FN and 
E-cadherin in the presence or absence of 8 ng/mL TGF-b1 stimulation. D. Histogram shows the quantitative results of 
Figure 6C. E. The influence of c-Ski and c-Ski-shRNA on Smad3 phosphorylation with TGF-b1 stimulation; *p < 0.05, 
**p < 0.01, compared with GFP control; &p < 0.05, &&p < 0.01, compared with the c-Ski-shRNA-alone-treated group; 
##p < 0.01, compared with overexpressed c-Ski-treated group.
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muscle cell, a high expression of c-Ski was also 
detected, which first demonstrated the presence 
of c-Ski expression in H9C2 cells, was distributed 
in the nucleus and cytoplasm and it could play 
a role in cytological biological function. c-Ski was 
reported to function as a negative regulator of 
TGF-b signalling [14, 15], which is closely related 
to the occurrence and development of myocardial 
fibrosis, yet the direct and precise effect of c-Ski 
on managing myofibroblast function and cardiac 
fibrosis remains unclear. 
In this study, 3 pairs of c-Ski-shRNA sequenc-
es were designed and synthesized in vitro using 
online software, according to the design principle 
of shRNA. c-Ski in H9C2 cells were silenced or 
overexpressed through constructing a lentiviral 
vector of c-Ski or sh-c-Ski to detect the expression 
of c-Ski mRNA and protein by RT-PCR and western 
blot after transfection into 293T cells by liposome 
transfection. Data collected confirmed that these 
3 pairs of sequences had a function of interference. 
Therein, the shRNA-3 gene silencing of the c-Ski 
in H9C2 cells could obtain a stable and desirable 
knockout efficiency and the decreased expression 
of c-Ski could still be present in cells after 7 d of 
transfection. Therefore, this method was used 
in the follow-up experiments. Overexpression of 
c-Ski abolished TGF-b — induced growth inhibition 
[16, 17]. Inhibition of TGF-b signalling is thus re-
garded as part of the mechanism of oncogenesis by 
Ski proteins. Similarly, it also proved that c-Ski had 
a positive effect on promoting H9C2 cell growth, 
but compared with the control and shScramble 
groups after stably silencing c-Ski, the cell prolif-
eration rates were not significantly different within 
96 h transfection. However, the ability of c-Ski 
gene silencing to suppress cell proliferation was 
gradually enhanced, and inhibition efficiency was 
the highest after 6 to 7 d of transfection. This out-
come suggests that c-Ski-shRNA could induce the 
proliferation inhibition of cardiac muscle cells in the 
long term. Its possible mechanism was regulating 
the transcription of nuclear factor, and suppressing 
the transcription of TGF-b downstream Smad2 and 
Smad3. These genes regulated many cell signals 
related to proliferation and differentiation; for ex-
ample, Smad3 promoted apoptosis by promoting 
the process of P21 and P15 inhibiting cell prolif-
eration [18–20]. Therefore, c-Ski may participate 
in cell proliferation through the abovementioned 
pathways, affecting cell viability. However, the 
potential molecular mechanism of this process 
remains to be investigated. This study found that 
the ability of cell migration was increased within 
a short time (≤ 24 h) after c-Ski knockdown, sug-
gesting that H9C2 cells may express some skeletal 
proteins or turn to fibroblasts after c-Ski silencing. 
Previous studies have demonstrated that TGF-b, 
as the best characterized fibrogenic growth factor 
[21], is markedly and consistently activated in 
experimental models of cardiac fibrosis [22] and 
in fibrotic human hearts [23]
For nearly a decade, much research showed 
that EMT is involved in a variety of tissue fibro-
sis and is a direct contributor to the fibroblast/ 
/myofibroblast population in the development of 
tissue fibrosis, such as myocardial, renal and liver 
fibrosis [24]. TGF-b1-induced EMT can promote 
myofibroblast transformation, which is prominently 
involved in the fibrotic processes [9]. In this study, 
activation and phenotype transformation of H9C2 
cells from resident cardiac muscle cells into myofi-
broblasts could have resulted from the knockdown 
of c-Ski, and showed as the up-regulated expres-
sion of a-SMA, a specific marker of myofibroblasts. 
The proportional reduction and fibrosis of cardiac 
muscle cells may cause heart failure, which is char-
acterized as pathological ventricular remodeling 
and is the main cause of death in patients with is-
chemic heart disease. The present results suggest 
that c-Ski-shRNA may induce cardiac disease by 
reducing the proportion of H9C2 cells, increasing 
the cell migration capacity and inducing phenotype 
transformation of H9C2 cells.
TGF-b1 affects the entire epithelial cell EMT 
process. TGF-b1-induced EMT plays an important 
role in cardiac fibrosis. Thus, this study further in-
vestigated the detailed function and mechanisms of 
c-Ski in TGF-b-induced EMT by stimulating H9C2 
cells with TGF-b1. In the study of human proximal 
tubule epithelial cells [25], the down-regulation of 
c-Ski reduced the response threshold of TGF-b, 
creating an ideal “fibrogenic” environment for 
TGF-b, which amplified the TGF-b effect. In con-
trast, by overexpression of c-Ski, the amount of 
TGF-b increased to 10-fold, and could not com-
pletely inhibit the expression of E-cadherin and 
induce the expression of a-SMA [26, 27]. In the 
present study, findings showed that c-Ski expres-
sion was down-regulated by TGF-b in a concen-
tration-dependent manner. EMT is characterized 
by the loss of epithelial characteristics and the 
acquisition of mesenchymal characteristics [28]; 
loss of epithelial markers, such as E-cadherin and 
the induction of mesenchymal markers including 
a-SMA and vimentin, which are hallmarks of early- 
and late-stage events of EMT, respectively [29]. In 
this study, the influence of c-Ski on the expression 
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levels of EMT-related proteins were measured 
(a-SMA, FN and E-cadherin) to evaluate c-Ski-shRNA 
auxo-action on TGF-b1-induced EMT. The results 
indicated that TGF-b1 stimulation could lead to ob-
vious down-regulated expression of E-cadherin, an 
important functional adhesive molecule, which af-
fects the adhesion among cells [30]. In addition, the 
expression of E-cadherin could also be significantly 
down-regulated by c-Ski-shRNA. TGF-b activation 
in the cardiac interstitium which promotes a-SMA 
transcription in fibroblasts through activation of the 
Smad3 signalling cascade [31]. Additionally, further 
investigation of the effect of c-Ski on Samd3 phos-
phorylation found that c-Ski-shRNA also promoted 
the phosphorylation of Samd3 induced by TGF-b1. 
Interestingly, c-Ski could restore E-cadherin ex-
pression while suppressing a-SMA and/or FN 
expression stimulated by TGF-b1. However, 
shRNA-induced c-Ski knockdown aggravated only 
the TGF-b1-induced EMT. These results suggest 
that the knockdown of c-Ski in H9C2 may result 
in an increased TGF-b biologic effect on the oc-
currence and development of cardiac fibrosis by 
inhibiting cardiac muscle cell proliferation, pro-
moting cell migration, down-regulating E-cadherin 
expression and increasing Smad3 phosphorylation. 
Conclusions
The above results indicated that c-Ski-shRNA 
silenced the c-Ski gene and regulated the prolifera-
tion and phenotype transformation of H9C2 cells 
through TGF-b1-induced EMT. Therefore, c-Ski 
may be closely associated with TGF-b1-induced 
EMT and play an important role in cardiac fibrosis 
development and progression.
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